The AstraZeneca Saga
By all accounts, Oxford and AstraZeneca made a good vaccine. So why has the path to approval been so painful?
Listen & Subscribe
Choose your preferred player:
Get Your Slate Plus Podcast
If you can't access your feeds, please contact customer support.
Listen on your computer:
Apple Podcasts will only work on MacOS operating systems since Catalina. We do not support Android apps on desktop at this time.
Listen on your device:RECOMMENDED
These links will only work if you're on the device you listen to podcasts on.
Set up manually:
Episode Notes
Back in April 2020, AstraZeneca was hailed as a frontrunner in the race to get an effective vaccine to market. A year later, after a series of trial pauses, communication blunders, and PR problems, the vaccine is on the cusp of FDA approval.
By all accounts, the company succeeded in making a safe, effective vaccine. So why has there been so much confusion about its rollout?
Guest:
Peter Aldhous, science reporter at Buzzfeed News